Colorectal Cancer
Colorectal cancer is a type of cancer that starts in the colon or rectum, often leading to symptoms such as changes in bowel habits, blood in the stool, and abdominal discomfort.
Colorectal Cancer: Telisotuzumab Adizutecan Treatment
We are studying a new treatment for adults with colorectal cancer who have positive circulating tumor DNA but no visible disease. The goal is to see if this treatment improves disease-free survival compared to standard care.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Do you have colon or rectal cancer (adenocarcinoma)?
- Have you received at least 3 months of chemotherapy that included platinum-based drugs?
- Have you had a CT scan in the last 6 weeks that showed no signs of cancer?
- Are you currently positive for circulating tumor DNA (ctDNA) after your last treatment?
- Do you have a history of lung disease that required steroid treatment?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Telisotuzumab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Region Midtjylland
Oncology
Århus, Denmark
Odense University Hospital
Oncology
Odense, Denmark
Sygehus Lillebaelt Vejle Sygehus
Oncology
Vejle, Denmark
Sponsor: AbbVie Deutschland GmbH & Co. KG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.